Advertisement
YOU ARE HERE: LAT HomeCollections

Business Briefing

Pharmaceuticals

Amgen touts drug study results

August 18, 2009|Times Wire Reports

Amgen Inc. said its cancer drug Vectibix was effective for advanced colon cancer patients as a second-line therapy, a finding consistent with results released Aug. 6 for the therapy as an initial treatment.

A study found that Vectibix "significantly improved" the time before symptoms worsened in advanced colon cancer patients with a certain gene mutation, the Thousand Oaks company said.

Advertisement
Los Angeles Times Articles
|
|
|